CTOR logo

CITIUS ONCOLOGY INC

CTORNASDAQ
🏆 #4098 by market capEarnings Dec 21US Equity
$1.05▼ $0.01 (−0.94%)
Market closed · at close
🔔
Track CTOR
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.9%
7d▲ 2.8%
14d▲ 9.5%
30d▲ 27.3%
ytd▲ 7.3%
1y▼ 47.5%
🏦Market Cap
$98M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
80
Good

Trading Snapshot

Day Range
$1.04 – $1.06
52-Week Range
$0.49 – $2.25
Volume
$2.42B
Avg Volume
$1.91B
Shares Outstanding
93.0M
Next Earnings
Oct 26, 2026

Fundamentals Snapshot

Annual Revenue
$41M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.48
Dividend Yield
—
Dilution (1yr)
+22.2%

Why Investors Own CTOR

  • ✓High-growth profile — revenue up +20.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 76% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CTOR logo

CITIUS ONCOLOGY INC

CTOR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$24M▲ +14.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▼ −4446.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
87.5M▲ +22.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▲ +$7M YoY
StockOtter · stockotter.space

About CITIUS ONCOLOGY INC

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$1.09
▲ +4.1% Upside
High Target$1.33
Low Target$0.99
Based on 26 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

CITIUS ONCOLOGY INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift CTOR price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

CITIUS ONCOLOGY INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.